U.S. Semiconductors Stock News

Ames National (ATLO) has just wrapped up FY 2025 with fourth quarter revenue of US$19.3 million and EPS of US$0.73, capping a trailing twelve month run of US$65.8 million in revenue and EPS of US$2.14 that coincides with 86.2% earnings growth and a net profit margin of 28.9% over the last year. The company has seen revenue move from US$53.5 million and EPS of US$1.14 on a trailing basis at the end of 2024 to the latest trailing totals, which may help provide a clearer picture of earnings...

Perrigo, a major holding in the Invesco High Yield Dividend ETF (PEY), has recently come under scrutiny as it pays out more in dividends than it earns, reflecting pressures from weaker business performance. This mismatch between earnings and dividends raises a material question for income-focused investors: how reliable is Perrigo’s payout policy over time? We’ll now examine how concerns about Perrigo’s dividend sustainability shape its broader investment narrative for current and...

Gold Resource (GORO) is back in focus after a temporary work stoppage at its Don David mine in Oaxaca, driven by an illegal access blockade linked to a dispute among contractor affiliated union factions. See our latest analysis for Gold Resource. The recent contractor blockade comes after a period of strong share price momentum, with a 90 day share price return of 115.85% and a 1 year total shareholder return of 234.72%. However, the 5 year total shareholder return of a 40.59% decline shows...

PROCEPT BioRobotics has drawn increased attention for its AquaBeam Robotic System for benign prostatic hyperplasia, as investors react to past and upcoming regulatory and clinical milestones that were seen as potentially meaningful for the technology’s medical adoption prospects. An interesting angle is how options trading around these anticipated approvals and trial readouts has become a focal point for investors seeking to position around milestone-driven volatility. We’ll now examine how...

Affinity Bancshares (AFBI) has reported solid headline numbers for FY 2025 so far, with third quarter total revenue of US$8.3 million and basic EPS of US$0.35, supported by trailing twelve month revenue of US$31.8 million and EPS of US$1.19. Across the last few reported quarters, revenue has moved from US$7.4 million in Q4 2024 to US$7.8 million in Q1 2025, US$8.3 million in Q2 2025 and US$8.3 million in Q3 2025. Over the same stretch, quarterly EPS has gone from US$0.21 to US$0.29, US$0.34...

SEALSQ Corp and WISeKey’s subsidiary recently signed a non-binding Memorandum of Understanding with the Government of Gujarat and Kaynes SemiCon to collaborate on establishing India’s first secure semiconductor design, test, and personalization center focused on post-quantum cryptography at Sanand, targeting capacity of up to 300 million secure chips annually. This planned joint venture, SEALKAYNESQ Ltd, is intended to support India’s onshore, quantum‑resistant semiconductor ecosystem for...

If you are wondering whether FTAI Aviation's current share price lines up with its fundamentals, you are not alone. Many investors are asking the same question right now. The stock last closed at US$292.10, with returns of 6.7% over 7 days, 67.7% over 30 days, 38.9% year to date and 224.2% over 1 year, with the 3 year and 5 year returns both very large. Recent coverage around FTAI Aviation has focused on how its business model fits into broader themes in the aviation and leasing industry, as...

In recent weeks, Progyny received a series of analyst upgrades after meetings with management highlighted strong demand for its fertility benefits platform, improved earnings visibility, and nearly complete client retention heading into 2026. Analysts also emphasized Progyny’s breadth of over 600 employer clients and the absence of any single customer contributing more than 5% of revenue, underlining the resilience of its business model. Next, we’ll examine how this combination of...

If you are wondering whether Pursuit Attractions and Hospitality is offering fair value at its recent price, this article walks through the numbers in a straightforward way so you can judge for yourself. The stock recently closed at US$35.25, with returns of 5.3% over the last 7 days, 2.9% over 30 days, 5.5% year to date, 22.8% over 3 years and a 9.1% decline over 1 year, which gives a mixed picture of recent and longer term performance. Outside of regular trading updates, investors have...

If you are wondering whether STAAR Surgical's share price reflects its true value today, it helps to step back and look at how the market has been treating the stock recently. Over the last week, the share price return was 8.7% lower. The 30 day, year to date and 1 year returns were 18.0%, 18.9% and 21.7% lower respectively, and the 3 year and 5 year returns were 73.4% and 81.3% lower. This gives important context before judging any potential upside or downside. Recent coverage around STAAR...

If you are asking whether NCR Atleos at US$37.63 is a bargain, fully priced, or something in between, this article is going to walk you through the key signals that matter for valuation. The stock has moved around recently, with a 5.8% decline over the last 7 days, a 3.5% decline over the last 30 days, and returns of 1.1% year to date and 15.7% over the last year. Recent coverage has focused on NCR Atleos as a stand alone ATM and financial technology infrastructure business following its...

Riverwater Partners Sustainable Value Strategy has initiated a new position in Adeia Inc. (NasdaqGS:ADEA). The position reflects fresh institutional interest in Adeia's intellectual property business across media and semiconductor markets. Adeia focuses on licensing intellectual property that underpins media content distribution and semiconductor design, areas that remain central to how video is delivered and how chips are structured and manufactured. As streaming, connected devices and...

Omnicell, ticker NasdaqGS:OMCL, has expanded its digital healthcare focus with new medication management solutions. The company has launched its XT Amplify program, aimed at supporting hospitals and health systems with medication management. These moves highlight Omnicell's efforts to align its portfolio with outcome focused digital healthcare trends. At a share price of $50.3, Omnicell is coming off a mixed return profile, with the stock up 8.4% over the past 30 days and 11.4% year to...

Arbe Robotics (ARBE) is attracting fresh attention after a sharp move in both its shares and options, with recent trading sessions showing concentrated call option activity and heavier volumes than the average month. See our latest analysis for Arbe Robotics. The latest options activity comes after a volatile stretch where the 7 day share price return of 49.12% and 30 day share price return of 65.05% contrast with a 1 year total shareholder return loss of 43.14%. This suggests short term...

If you are wondering whether Interparfums at around US$98.76 is attractively priced or asking too much for its brand power, you are in the right place. The stock has recently shown sharp moves, with returns of 9.8% over 7 days and 15.8% over 30 days. It also carries a 27.8% decline over 1 year and a 6.1% decline over 3 years, alongside a 77.3% gain over 5 years. These mixed returns come against a backdrop of ongoing attention on branded fragrance and beauty companies, where investors have...

If you are wondering whether Assurant at around US$233 per share still offers value, you are not alone. The stock’s current price invites a closer look at what you are actually paying for. The share price closed at US$233.39, with returns of a 0.3% decline over 7 days, a 3.5% decline over 30 days and a 1.8% decline year to date, while the 1 year and 3 year returns stand at 12.4% and 88.5% respectively, and the 5 year return is 87.9%. Recent price moves sit against a backdrop of ongoing...

In January 2026, Manas AI announced a multi-year agreement granting it extensive access to Schrödinger’s physics-based computational drug discovery platform and expert support, aimed at integrating this technology with its AI “world model” for identifying diverse molecular binders. A key angle for investors is that Schrödinger’s tools will be tightly embedded into Manas AI’s large-scale discovery workflows, potentially reinforcing Schrödinger’s position in AI-enabled molecular design...

Oruka Therapeutics, Inc. recently reported positive interim data from its first-in-human Phase 1 trial of ORKA-002, showing a long half-life, sustained IL-17 inhibition and a class-consistent safety profile in healthy volunteers, while outlining multiple ongoing and planned psoriasis and hidradenitis suppurativa studies across its ORKA-001 and ORKA-002 programs. A key insight for investors is the early clinical evidence suggesting ORKA-002 may enable twice-yearly maintenance dosing,...

Earlier this month, Qnity Electronics reaffirmed its full-year 2025 net sales guidance of about US$4.70 billion and announced that long-time finance executive Mike Goss will serve as Interim Chief Financial Officer following Matt Harbaugh’s health-related departure. The combination of steady guidance and a seasoned interim CFO, who brings nearly three decades of experience at DuPont and Ernst & Young, has sharpened investor focus on Qnity’s role as a newly independent supplier of...

Burford Capital (NYSE:BUR) has drawn fresh attention after launching a planned $450 million private offering of senior notes due 2034. The proceeds are earmarked to redeem 2026 bonds and for broader corporate uses. See our latest analysis for Burford Capital. The planned 2034 notes come after a period of mixed market signals, with a 30-day share price return of 8.33% and a year-to-date share price return of 11.43%. The 1-year total shareholder return is 29.46% lower, suggesting recent...

Caledonia Mining (CMCL) has packed a lot into its latest update, combining Q4 and full year 2025 production figures, fresh 2026 guidance, a COO departure, and new convertible bond financing. See our latest analysis for Caledonia Mining. Those production figures, new 2026 guidance, COO departure and fresh convertible notes have landed alongside a strong share price move. The 1 day share price return is 6.05%, the 7 day return is 15.36%, the 30 day return is 15.91% and the year to date return...

POET Technologies recently completed a registered direct follow-on equity offering of 20,689,656 common shares at US$7.25 each, raising about US$150.00 million to fund acquisitions, research and development, and expansion of its optical module and light source businesses. This capital raise follows POET’s Product Innovation Award in China for its Teralight 1.6T optical engines, highlighting management’s intent to scale its AI-focused photonics platform using fresh institutional...

BillionToOne (BLLN) is back on investors’ radar after recent trading, with the share price around US$87.57 and mixed short term returns, including a 3.3% decline over the past day and a modest gain over the month. See our latest analysis for BillionToOne. Despite the recent 3.3% one day share price decline and a slightly negative year to date share price return of 1.93%, BillionToOne’s 1.42% 30 day share price return suggests momentum has been cautious rather than strongly trending in either...

Datavault AI Inc. recently presented at the ICR Conference 2026 in Orlando and is set to appear at the DealFlow Discovery Conference in Atlantic City, where CEO Nathaniel T. Bradley is discussing the company’s focus on real-world asset tokenization and broader technology portfolio. These conference appearances highlight Datavault AI’s effort to raise its profile with institutional investors and analysts by showcasing its tokenization strategy and long-term growth initiatives through formal...